KVUE

#412
Kenvue Inc.
17.2650 USD
-0.66%
版块: 消费防御
基础: USD
利润货币: USD
日范围
17.2600
17.2800
年范围
14.0200
19.1750
日变化
-0.66%
每月变动
-1.90%
6个月变化
+14.49%
年变化
+14.49%
前一天收盘价
17.3800
开盘价
17.2750
买价
卖价
最低价
17.2600
High
17.2800
交易量
183
展开完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 33.0924 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
22.62
市销率
2.19
每股股息
0.82
股息收益率 %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

新闻